Over the past five years, CRISPR Therapeutics (CRSP) has significantly underperformed the broader market. There are multiple reasons behind this: a challenging macroeconomic environment has led investors to pull capital from more speculative assets, and the company’s only approved drug to date has generated meager sales, failing to boost market confidence. However, over the long term, one key factor could drive exceptional returns for the stock—its pipeline has the potential to redefine entire therapeutic areas.
CRISPR Therapeutics currently has a market capitalization of just under $5 billion and boasts a substantial number of pipeline candidates. Leveraging its gene-editing platform, the company is focusing on several therapeutic areas with high unmet needs. Among its most promising programs are those aimed at addressing risk factors for cardiovascular disease.
Take the candidate CTX310, for example, which is designed for patients with elevated LDL cholesterol and triglyceride levels due to certain genetic conditions or other causes. CTX310 targets the ANGPTL3 gene, inhibiting the function of the ANGPTL3 protein to regulate LDL and triglycerides—both of which, at excessively high levels, can lead to coronary artery disease.
CTX310 has the potential to redefine this therapeutic area for two reasons. First, CRISPR Therapeutics is focusing on high-risk patients who have limited treatment options under current standards of care. Second, while patients typically require long-term medication to lower LDL and triglycerides, CTX310, as a gene-editing therapy, could offer a one-time treatment with permanent effects. The company estimates that 40 million people in the United States suffer from high triglycerides and high LDL. Although CTX310 will not address the entire population, even targeting just 0.1% of that group (i.e., 40,000 patients) represents a substantial market opportunity, given the high unmet needs of these patients.
Another candidate, CTX320, aims to lower lipoprotein(a) levels—a risk factor for major cardiovascular events—in certain patients, similarly offering a potential one-time cure for eligible individuals. If approved, both drugs would represent major breakthroughs. Furthermore, CRISPR Therapeutics has other exciting pipeline programs, including at least one therapy that could lead to a functional cure for type 1 diabetes, which would also be a significant clinical success.
Nevertheless, the notable risks must be emphasized. CRISPR Therapeutics currently generates modest revenue and is not yet profitable. Despite the promising outlook for its pipeline, any clinical or regulatory setbacks could cause the stock price to decline.
Conclusion: CRISPR Therapeutics is a mid-cap biotech stock with significant potential, suited for investors who can tolerate higher risk and volatility. For risk-averse investors, however, it is best avoided.
